The Rest Of Europe POP Treatment and Management / Pelvic Organ Prolapse Market was valued at $5.9 Million in 2025 and projected to reach to $8.6 Million by 2030, representing a compound annual growth rate of 8.0%. Rest Of Europe represents a high-growth segment within the European POP treatment market, driven by increasing healthcare investments, rising awareness of pelvic floor disorders, and improving access to specialized gynecological care.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe's POP treatment market is expanding at 8.0% CAGR, outpacing the global average of 6.6%, indicating accelerating adoption of advanced treatment solutions across smaller European markets.
The market is projected to grow from USD 5.9 million in 2025 to USD 8.6 million by 2030, representing a 45.8% increase in market value over the five-year forecast period.
Rest Of Europe countries are investing in modernized healthcare systems and gynecological treatment facilities, creating opportunities for innovative POP management solutions and minimally invasive procedures.
Significant patient populations in Rest Of Europe remain underdiagnosed and undertreated for POP, presenting substantial market expansion potential as awareness campaigns and healthcare access improve.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | SACROCOLPOPEXY (Type) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 6.6% from 2025 to 2030 |
| Largest Segment | SURGICAL (Treatment) |
| Market Size Base Year (Billions) | ~USD 0.77 (2025) |
| Revenue Forecast (Billions) | ~USD 1.06 (2030) |
| Segments Covered | Product, Treatment, Type, Application, End User |
5 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPORATION | United States | Public Company | Cardiovascular (CRM, structural heart, peripheral interventions, LAAC),MedSurg Endoscopy (GI, pancreaticobiliary, single-use scopes, infection prevention),Urology and Pelvic Health, |
| COOPERCOMPANIES | United States | Public Company | Spherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services, |
| JOHNSON & JOHNSON | United States | Public Company | Oncology,Immunology,Neuroscience and Other Innovative Medicine, |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| INTEGRA LIFESCIENCES CORPORATION | United States | Public Company | Neurosurgery & Neurocritical Care (Codman Specialty Surgical),ENT, Navigation & Surgical Instrumentation,Tissue Technologies – Wound, Skin & Reconstruction, |
| FEG TEXTILTECHNIK FORSCHUNGS- UND ENTWICKLUNGSGESELLSCHAFT MBH | Germany | Private Company | Contract R&D and prototyping,Process engineering and scale-up services,Consulting, testing, and training, |
Boston Scientific Corporation is a publicly traded medical device company founded in 1979 and headquartered in the United States. With 59,000 employees, the company develops and manufactures a broad range of medical devices and technologies for various healthcare applications.
Cooper Companies is a publicly traded medical device company founded in 1958 and headquartered in the United States. With 15,000 employees, the company operates in the contact lens and eye care markets.
Johnson & Johnson is a publicly traded multinational healthcare company founded in 1886 and based in the United States. With 138,200 employees, the company operates across pharmaceuticals, medical devices, and consumer health segments.
GE Healthcare is a publicly traded medical technology company founded in 2022 and headquartered in the United States. The company employs 54,000 people and provides healthcare imaging, monitoring, and diagnostic solutions.
Integra LifeSciences Corporation is a publicly traded medical device company founded in 1989 and based in the United States. With 4,427 employees, the company develops and manufactures surgical instruments and regenerative medicine products.
FEG Textiltechnik Forschungs- und Entwicklungsgesellschaft mbH is a privately held company founded in 1991 and headquartered in Germany. The company specializes in textile technology research and development.
Rest Of Europe's POP treatment and management market is estimated at USD 5.9 million in 2025.
Rest Of Europe is forecasted to reach USD 8.6 million by 2030, representing 45.8% growth over the five-year period.
Rest Of Europe's 8.0% CAGR outpaces the global POP market CAGR of 6.6%, indicating stronger regional expansion momentum.
Rest Of Europe's growth is driven by aging populations, increased clinical awareness, adoption of minimally invasive techniques, and improved reimbursement policies.
Rest Of Europe shows increasing adoption of both minimally invasive surgical options and conservative management approaches for pelvic organ prolapse.
The study involved major activities in estimating the current market size for the POP Treatment and Management / Pelvic Organ Prolapse market. Exhaustive secondary research was done to collect information on the POP Treatment and Management / Pelvic Organ Prolapse industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the POP Treatment and Management / Pelvic Organ Prolapse market.
The four steps involved in estimating the market size are:
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS)] to identify and collect information for the global POP Treatment and Management / Pelvic Organ Prolapse market study. Secondary sources were also used to obtain important information about the key players, market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the POP Treatment and Management / Pelvic Organ Prolapse market. The primary sources from the demand side included pharmaceutical companies, biotechnology companies, CROs, medical device companies, and research academics and universities. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends & key market dynamics.
The following is a breakdown of the primary respondents:
Note 1: Other designations include sales, marketing, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global POP Treatment and Management / Pelvic Organ Prolapse market. All the major service providers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. The global POP Treatment and Management / Pelvic Organ Prolapse market was split into various segments and sub-segments based on:
The research methodology used to estimate the market size includes the following:

After arriving at the overall market size by applying the processes mentioned above, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Pelvic organ prolapse (POP) is a condition in which the pelvic organs—such as the vagina, uterus, bladder, or rectum—descend from their normal anatomical positions. This occurs when the pelvic floor, composed of muscles, ligaments, and connective tissues that provide structural support to these organs, is weakened or stretched. The pelvic floor functions as a supportive structure beneath the pelvic organs. When these supportive structures lose strength or elasticity, the organs may shift out of place or protrude into the vaginal canal. Common causes of pelvic floor weakening include childbirth, aging, and other factors that increase intra-abdominal pressure.
Full forecast, segment splits, and company analysis for all POP Treatment and Management / Pelvic Organ Prolapse Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report